Unknown PHASE1 INTERVENTIONAL 3-arm NCT03600649

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas

Sponsor: National Pediatric Cancer Foundation

Conditions Angiomatoid Fibrous Histiocytoma Clear Cell Sarcoma Desmoplastic Small Round Cell Tumor Ewing Sarcoma Extraskeletal Myxoid Chondrosarcoma Fibromyxoid Tumor Myoepithelial Tumor Myxoid Liposarcoma Primary Pulmonary Myxoid Sarcoma Sarcoma,Soft Tissue Sclerosing Epithelioid Fibrosarcoma

Interventions Cyclophosphamide Seclidemstat Topotecan

Updated 21 times since 2018 Last updated: Nov 20, 2023 Started: Jun 4, 2018 Primary completion: Sep 30, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Angiomatoid Fibrous Histiocytoma and Clear Cell Sarcoma, this trial is ongoing. The trial is conducted by National Pediatric Cancer Foundation and has accumulated 21 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

21 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE1

Status: Active Not Recruiting → Unknown
Sep 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE1
Sep 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
Dec 2023 — Jul 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 16 earlier versions

Sep 2022 — Dec 2023 [monthly]

Recruiting PHASE1
Feb 2022 — Sep 2022 [monthly]

Recruiting PHASE1
Oct 2021 — Feb 2022 [monthly]

Recruiting PHASE1
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE1
May 2021 — Sep 2021 [monthly]

Recruiting PHASE1
Apr 2021 — May 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE1
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Feb 2020 — Nov 2020 [monthly]

Recruiting PHASE1
Dec 2019 — Feb 2020 [monthly]

Recruiting PHASE1
Mar 2019 — Dec 2019 [monthly]

Recruiting PHASE1
Feb 2019 — Mar 2019 [monthly]

Recruiting PHASE1
Dec 2018 — Feb 2019 [monthly]

Recruiting PHASE1
Nov 2018 — Dec 2018 [monthly]

Recruiting PHASE1
Oct 2018 — Nov 2018 [monthly]

Recruiting PHASE1
Aug 2018 — Oct 2018 [monthly]

Recruiting PHASE1

First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Pediatric Cancer Foundation
Salarius Pharmaceuticals, LLC

Data source: Salarius Pharmaceuticals, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Boston, United States , Cleveland, United States , Columbus, United States , Fairfax, United States , Houston, United States , Jacksonville, United States , Los Angeles, United States , New York, United States , Philadelphia, United States , Portland, United States and 6 more locations